European equities markets saw significant advances on Thursday. The FTSE Eurofirst 300 added 1 percent to close at 1,530.13, a six-year high.
Insurer Axa added 2.6 percent to €33.18 on a full-year report that showed sales 10 percent higher. The results brought an upgraded target share price, up from €34.50 to €36.10 from UBS, which also repeated its “buy” rating.
Elsewhere among financials, banks were higher after Deutsche Bank said that it made a record profit of €6 billion in 2006 due to growth in income from investment banking and trading. While Deutsche Bank ended the day even at €108.45, UBS was up 1.2 percent to €78.70 and Societe Generale gained 1.4 percent to €137.40. Anglo Irish Bank was 3.2 percent higher to €16 placement of 35.71 million shares in order to raise funds for expansion.
The oil sector gained on Royal Dutch Shell’s report that it had underlying profits of 2.6 percent in the fourth quarter, better than had been anticipated. Shell added 2 percent to €26.50, while OMV gained 1.3 percent to €41.62 and Total was 1.6 percent higher to €52.65.
The pharmaceuticals sector was higher on news from UK company AstraZeneca that it will emphasize joint ventures and cut jobs to promote growth. Novartis added 1.1 percent to SFr72.30 on an upgrade from JP Morgan, which raised the drug maker’s recommendation from “neutral” to “overweight” and upped its target share price from SFr74 to SFr81. Santhera Pharmaceuticals added 23.6 percent to SFr119.90 on an upgrade of its target share price from SFr123 to SFr175 from Deutsche Bank. Santhera expects an early approval of its treatment for a neuromuscular disease from the US Food and Drug Administration.